摘要
目的 研究尿激酶型纤溶酶原活因子 (uPA)及其受体 (uPAR)在神经母细胞瘤 (NB)中的表达和意义。方法 应用免疫组织化学方法研究uPA及uPAR在 42例神经母细胞瘤中的表达 ,并应用逆转录 聚合酶链式反应 (RT PCR)方法检测患儿骨髓和外周血中的神经蛋白基因产物9.5(PGP9.5)。结果 uPA及uPAR阳性表达率在进展期肿瘤 (均为 85 .7% )高于局灶期肿瘤(42 .9% ,2 8.6 % ) ;预后不良型患儿 (91 .7% ,83 .3 % )高于预后良好型患儿 (均为 44 .4 % ) ,且差异均具有非常显著性 (P <0 .0 1 )。患儿骨髓和外周血中PGP9.5阳性检出率在uPA阳性患儿组(60 .0 % )显著高于uPA阴性患儿组 (8.3 % ,P <0 .0 1 ) ;uPAR阳性组 (57.1 % )高于uPAR阴性组(2 1 .4 % ,P <0 .0 5)。uPA和uPAR同时阳性的 1 0例患儿 ,骨髓和外周血中均有PGP9.5阳性表达 ,而同时阴性的 5例患儿中 ,均未检测到PGP9.5。
Objective To investigate the expression of urokinase type plasminogen activator (uPA) and its specific receptor (uPAR) in neuroblastoma (NB).Methods The expression of uPA and uPAR was detected by immunohistochemical method in 42 cases of NB.Neuroendocrine protein product 9.5 (PGP9.5) mRNA was measured by reverse transcription polymerase chain reaction (RT PCR) to identify NB cells in peripheral blood and bone marrow.Results The positive rate of uPA and uPAR in advanced stage tumors (both 85.7%) was remarkably higher than in focal stage tumors (42.9%and 28.6% respectively) (P<0.01).In the cases of poor progrosis,the positive rate of uPA and uPAR (91.7% and 83.3% respectively) was higher than in those with favorable progrosis (both 44.4%) (P< 0.01). There was significant difference in the positive rate of PGP9.5 between the group positive for uPA (60.0%) and the group negative for uPA (8.3%) (P<0.01),and so was between the group positive for uPAR (57.1%) and the group negative for uPAR (21.4%) (P<0.05).PGP9.5 was detectable in 10 cases of NB both positive for uPA and uPAR,whereas PGP9.5 was not detectable in the 5 cases both negative for uPA and uPAR.Conclusion uPA and uPAR may play an important role in invasion and metastasis of NB.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2002年第2期137-138,T004,共3页
Chinese Journal of Experimental Surgery
